FDA USER FEE REPORTS TO CONGRESS: "SO FAR, SO GOOD,"
FDA USER FEE REPORTS TO CONGRESS: "SO FAR, SO GOOD," House Energy & Commerce Committee health staffer Kay Holcombe told the Drug Information Association annual meeting in Washington, D.C. June 6. Congress received FDA's report on the implementation of the drug user fee act on June 3, Holcombe said, about "six months late" ("The Pink Sheet" May 16, p. 5). The report is "a very positive sign that indeed there is a commitment at FDA to meet the goals that it committed to meet" when the drug user fee act passed in June 1992, Holcombe said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth